Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex

Area of Science:

• Cardiovascular Research
• Muscle Biology
• Genetics

Background:

• Duchenne muscular dystrophy (DMD) and limb girdle muscular dystrophy (LGMD) 2C-F stem from mutations in dystrophin and sarcoglycan proteins, respectively.
• Dystrophin and sarcoglycans are crucial cytoskeletal and membrane-associated proteins in muscle, with complex functional interdependencies.
• Previous studies suggest differing roles in skeletal muscle susceptibility to damage.

Purpose of the Study:

• To investigate and compare the distinct cardiac myocyte dysfunction mechanisms in mouse models of DMD, LGMD-2C, and LGMD-2F.
• To elucidate the specific roles of dystrophin versus sarcoglycans in cardiac mechanical integrity and function.

Main Methods:

• Utilized mouse models deficient in dystrophin (DMD), gamma-sarcoglycan (LGMD-2C), and delta-sarcoglycan (LGMD-2F).
• Assessed cardiac myocyte passive compliance and susceptibility to contracture.
• Conducted in vivo dobutamine stress testing and catheter-based hemodynamic studies.
• Performed histopathological analysis of cardiac tissue for fibrosis.

Main Results:

• Dystrophin-deficient cardiac myocytes exhibited poor passive compliance and contracture susceptibility, unlike sarcoglycan-deficient myocytes.
• Dystrophin-deficient mice showed reduced survival and the poorest cardiac function during stress tests.
• Sarcoglycan-deficient hearts displayed increased fibrosis, whereas dystrophin-deficient hearts did not.

Conclusions:

• Dystrophin plays a critical role in protecting cardiac myocytes against mechanical damage, a function not shared by gamma- or delta-sarcoglycans.
• Distinct pathogenic mechanisms underlie dystrophinopathies and sarcoglycanopathies, leading to differential cardiac outcomes.
• This study highlights the unique protective role of dystrophin in the heart.